This is a livestream recording of the NHS England board meeting that took place on 5 February 2026. This recording can be made available in a different format on request. Please contact us ...

This self-assessment tool has been developed to help trust teams assess and provide board-level assurance on the safety, quality and delivery of non-elective care in the first 72 hours in hospital, ...

NHS England » The Model Acute Pathway: standards for care of acutely unwell patients in their first 72 hours in hospital ...

NHS National Medical Director Professor Meghana Pandit said: “Early NHS preparation and planning for winter is paying off for patients. “Patients are being handed over from ambulances quicker, even ...

Elizabeth O'Mahony, Interim Director General, Finance / Chief Financial Officer Paper type: For discussion 5 February 2026 ...

This guidance provides strategies that optimise chronic obstructive pulmonary disease (COPD) care across the pathway and offer integrated care boards a consistent methodology and set of strategies for ...

notify the UKHSA duty officer (National Response Centre) and the Department of Health and Social Care (DHSC) duty officer, of a countermeasure request (for biological, radiological and nuclear (BRN) ...

Jules Hunt, DG Technology, Digital and Data - Ming Tang, CDIO (interim) / Chief Data and Analytics Officer - Ayub Bhayat, Director of Data Services / Deputy CDAO - David Ashby, Director of Clinical an ...

NHS England » Health and care professionals should feel empowered to promote physical activity to their patients, and this is how we can support them ...

The aim of this report is to understand stakeholder perceptions of the new patient premium (NPP) scheme by reporting on a series of focus groups held in November 2024.

This publication aims to improve treatment and care for adults with chronic obstructive pulmonary disease (COPD). It provides commissioners with strategies and recommendations for frontline care, ...

The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...